Mismatch repair and treatment resistance in ovarian cancer. - Wikidata - awgldk - TriplyDB

Mismatch repair and treatment resistance in ovarian cancer.

Mismatch repair and treatment resistance in ovarian cancer.

http://www.wikidata.org/entity/Q33252378

about

Chemoresistance and targeted therapies in ovarian and endometrial cancers A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.Overview of a chemoresponse assay in ovarian cancer A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer Features of ovarian cancer in Lynch syndrome (Review).Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1 Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America.Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells.Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.Pharmaco(epi)genomics in ovarian cancer.Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.Role of epigenomics in ovarian and endometrial cancers.Oxaliplatin for the treatment of ovarian cancer.Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.Platinum(ii) O,S complexes as potential metallodrugs against Cisplatin resistance.Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.Prediction of therapy response in ovarian cancer: Where are we now?Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.DNA damage repair in ovarian cancer: unlocking the heterogeneity.Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin.

P2860

Q28073246-E4024BDE-4737-4B82-A2D0-B3B2A7307580 Q28283356-C75932EC-239E-4136-819B-E2A4CA956C4C Q28543021-81942436-D56B-4C6D-8702-2F128801C781 Q33882357-A8DB59EE-80EA-439C-81AD-832E33E4218E Q34071625-0A8965E0-B212-4BA7-B476-3A278CE4E98C Q34091420-C0180990-B05D-48D7-B8AC-7DF84D197CE0 Q34265940-4C2AE00A-FE63-4546-BCCF-F394E67B3738 Q34692155-5BDFD977-B625-428E-B0EB-5C7B0258B614 Q34833628-A4AD0FB4-F619-4211-803F-56955CE1B7D3 Q35023943-F95A827D-30DD-40ED-8C31-E2602D9D0FE7 Q36375191-EFB8AF1C-4FB3-4435-96D2-8613A32BCE43 Q36497294-CDB57163-6745-4EA5-85FC-044C43035920 Q36691820-8D9AE029-BB27-487E-9D48-5F0A53FD1BA1 Q37287437-D27BFE11-660F-40A8-A307-0AFDA07B43BB Q37346198-93EE7DC7-6650-4578-B7FF-B46A3548F6F9 Q37611723-A614BB9F-137F-490D-A352-DBF5F64A8BA5 Q37933098-B21D5C92-0A97-435A-8AAD-0CF85B8EA565 Q37961734-7696042D-11BB-4F61-870B-46B3D8E2CE14 Q38540596-689866B8-0346-45E3-9350-30842FE41BCD Q38544386-534DE7BA-51EA-446D-82B7-199296CE0F3E Q38728438-C9656172-5672-4FD3-8A20-BCE1FF206D2A Q39198408-D1783BB4-4D00-47F3-B744-5B43E98A7B0B Q39263260-169C39B5-B670-4DE0-B0BE-E04E978FF955 Q53085805-46A383E2-97EA-40C2-9831-1A59A0E2EF47 Q55399645-ACD97500-52C1-43BA-8AA7-EBEB189014DF Q55716422-7FEF35CD-428D-4402-96EF-28F8CE1CA9B4

P2860

Mismatch repair and treatment resistance in ovarian cancer.

http://www.wikidata.org/entity/Q33252378

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Mismatch repair and treatment resistance in ovarian cancer.

@ast

Mismatch repair and treatment resistance in ovarian cancer.

@en

type

label

Mismatch repair and treatment resistance in ovarian cancer.

@ast

Mismatch repair and treatment resistance in ovarian cancer.

@en

prefLabel

Mismatch repair and treatment resistance in ovarian cancer.

@ast

Mismatch repair and treatment resistance in ovarian cancer.

@en

P1433

Q33252378-CC99631F-D192-4F9D-93C3-7F864AA3F052

P1476

Q33252378-177943B8-D339-48E9-9E88-4FA83A51F721

P2093

Q33252378-0FF0EB62-B9B9-4000-82BF-F8663CDDC848

Q33252378-1BD2B40C-5F20-4018-A0E2-32990AE7D64B

Q33252378-552CCA1E-AC23-4AAD-AD42-6A436A4619ED

Q33252378-5673218F-9F74-427A-AD21-68297B68B593

Q33252378-7F5D429F-D407-472B-A786-44DFE9E7557A

Q33252378-A8FDE825-8A2C-4FFE-BF70-893C233C51E9

Q33252378-ABA2896B-D44F-4804-A75E-133B5E7F0AD2

Q33252378-C1F0C9A1-B1D1-4DA1-ABB1-FA5EEBB9EB04

Q33252378-D327D0C9-ADD0-4034-8536-A237CC972C0A

P2860

Q33252378-1635310E-79A9-48A2-8480-A3EC385293F4

Q33252378-22562F72-651E-4CC3-89C4-DCB93658E38D

Q33252378-232AF880-CB86-4372-A454-4205CD92C278

Q33252378-25F6B026-7C20-404B-97A3-F14130C29C8B

Q33252378-28C70293-E900-4E60-80F9-AC949298CC96

Q33252378-28CF23FC-79F8-4C7C-9AE3-CA75A643D318

Q33252378-2EAC1545-B3CD-44A9-86E1-D4319B312404

Q33252378-32B2AE65-57A0-4323-9998-F4C3589C5994

Q33252378-33381CBC-C1E3-44E3-97E9-DAE30C7BE965

Q33252378-3430EE6E-E76B-4C71-ADB9-3A74BBB45F7F

P2888

Q33252378-42659064-989D-4F18-9CC1-89C0F516A863

P304

Q33252378-EBA4ED8F-EB63-4830-91A3-A225A009C643

P31

Q33252378-CFD72B38-7525-40FF-9767-E96D5019A50E

P356

Q33252378-0B19C6F9-FECA-4041-B96D-DE8557B97DDF

P407

Q33252378-CA4CC84E-9CE4-48C8-82B0-DB3B6044ADBA

P478

Q33252378-1726F520-4200-459B-A2BD-FCAA66AC1D95

P577

Q33252378-1F74D3BF-FB7F-49E9-8602-904A83E530A3

P5875

Q33252378-DC85AE47-6CB4-4FE0-91A9-EDA20A9D6775

P6179

Q33252378-247D905F-17A8-4FF2-8CF2-ED1EBD1CFF21

P698

Q33252378-5809EE5B-CA90-4D27-AFD9-B1A1F14A6B8F

P921

Q33252378-8D8F0E5E-AD15-4ECE-9F2D-EE548C4C4905

P932

Q33252378-42D76722-606E-4680-8FE6-D372630DDFED

P356

1471-2407-6-201

P1433

P1476

Mismatch repair and treatment resistance in ovarian cancer.

@en

P2093

Els M J J Berns

http://www.w3.org/2001/XMLSchema#string

Gerrit Stoter

http://www.w3.org/2001/XMLSchema#string

Iris L van Staveren

http://www.w3.org/2001/XMLSchema#string

Jozien Helleman

http://www.w3.org/2001/XMLSchema#string

Kirsten Ritstier

http://www.w3.org/2001/XMLSchema#string

Maria E L van der Burg

http://www.w3.org/2001/XMLSchema#string

Patricia C Ewing

http://www.w3.org/2001/XMLSchema#string

Patricia F van Kuijk

http://www.w3.org/2001/XMLSchema#string

Winand N M Dinjens

http://www.w3.org/2001/XMLSchema#string

P2860

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

Mouse models for human DNA mismatch-repair gene defects

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair

Proliferating cell nuclear antigen (PCNA): a dancer with many partners

Molecular profiling of platinum resistant ovarian cancer.

Involvement of the DNA mismatch repair system in antineoplastic drug resistance.

Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.

Cancer of the ovary.

P2888

1471-2407-6-201

P304

201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-6-201

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6906429

http://www.w3.org/2001/XMLSchema#string

P6179

1018622936

http://www.w3.org/2001/XMLSchema#string

P698

16879751

http://www.w3.org/2001/XMLSchema#string

P921

P932

1557864

http://www.w3.org/2001/XMLSchema#string